US › Healthcare

Lyell Immunopharma Inc (LYEL)

US · Healthcare · Biotechnology

$13.60+5.67%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2,000
Revenue YoY
-71.4%
Net profit
$-24.2M
Profit YoY
+53.7%
EPS
$-1.10
EPS estimate
$-2.36
Net margin
-1,207,650.0%

EPS came in at -1.10 against a street estimate of -2.36 — a beat of 53.4%.

Key statistics

Market cap
$301.9M
Forward P/E
0.0
P/B
1.16
Book value
$11.73
EPS (TTM)
$-13.62
52-week high
$45.00
52-week low
$9.28
50-day MA
$13.91
200-day MA
$20.63
Beta
-0.06

Analyst view

Analysts rate Lyell Immunopharma Inc a hold (0 buy, 3 hold, 1 sell out of 4) with an average price target of $38.14.

Shareholding

Insiders
39.16%
Institutions
56.95%

Largest institutional holders

FundStake
ARCH VENTURE CORP13.25%
GSK PLC6.17%
Foresite Capital Management IV, LLC3.27%
Orland Properties Ltd3.08%
Vanguard Capital Management, LLC2.93%
Almitas Capital LLC2.36%
Foresite Capital Management V, LLC1.95%
Millennium Management LLC1.87%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lyell Immunopharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.